Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer

被引：0
作者：
Samuel Murray
Vasilios Karavasilis
Mattheos Bobos
Evangelia Razis
Savvas Papadopoulos
Christos Christodoulou
Paris Kosmidis
George Fountzilas
机构：
[1] BioMarker Solutions Ltd,Department of Molecular Oncology
[2] GeneKOR,Department of Medical Oncology
[3] “Papageorgiou” Hospital,Department of Pathology
[4] Aristotle University of Thessaloniki School of Medicine,First Department of Medical Oncology
[5] Aristotle University of Thessaloniki School of Medicine,Department of Pathology
[6] “Hygeia” Hospital,Second Department of Medical Oncology
[7] “Hygeia” Hospital,Second Department of Medical Oncology
[8] “Metropolitan” Hospital,undefined
[9] “Hygeia” Hospital,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 31卷
关键词：
Predictive; Somatic mutation; EGFR; Gefitinib; Erlotinib; Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options?
    Morin-Ben Abdallah, S.
    Wong, A.
    CURRENT ONCOLOGY, 2018, 25 : S103 - S114
  • [22] A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada
    Hirsh, V.
    Melosky, B.
    Goss, G.
    Morris, D.
    Morzycki, W.
    CURRENT ONCOLOGY, 2012, 19 (02) : 78 - 90
  • [23] Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma
    Burotto, Mauricio
    Ali, Syed Abbas
    Coyne, Geraldine O'Sullivan
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (01) : 97 - 110
  • [24] Efficacy of tyrosine kinase inhibitors in non-small-cell lung cancer patients undergoing dose reduction and those with a low body surface area
    Sato, Shinya
    Kurishima, Koichi
    Miyazaki, Kunihiko
    Kodama, Takahide
    Ishikawa, Hiroichi
    Kagohashi, Katsunori
    Tamura, Tomohiro
    Homma, Shinsuke
    Satoh, Hiroaki
    Hizawa, Nobuyuki
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (04) : 604 - 608
  • [25] Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients
    Fan, Yun
    Huang, Zhiyu
    Fang, Luo
    Miu, Lulu
    Lin, Nengming
    Gong, Lei
    Yu, Haifeng
    Yang, Haiyan
    Mao, Weimin
    ONCOTARGETS AND THERAPY, 2013, 6 : 1789 - 1802
  • [26] Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer patients: A network meta-analysis
    Wu, Ziyang
    Chen, Suhua
    Du, Xin
    Wu, Yibo
    Xie, Xiaohui
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (02) : 310 - 318
  • [27] Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
    Renhua Guo
    Xiaofen Chen
    Tongshan Wang
    Zhiyuan Zhang
    Jin Sun
    Yongqian Shu
    BMC Cancer, 11
  • [28] Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
    Guo, Renhua
    Chen, Xiaofen
    Wang, Tongshan
    Zhang, Zhiyuan
    Sun, Jin
    Shu, Yongqian
    BMC CANCER, 2011, 11
  • [29] Molecular targeted therapy of patients with non-small-cell lung cancer
    Stencel, Katarzyna
    Swiniuch, Daria
    Ramlau, Rodryg
    ONCOLOGY IN CLINICAL PRACTICE, 2019, 15 (06): : 289 - 296
  • [30] Multiplicity of EGFR and KRAS Mutations in Non-small Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors
    Benesova, Lucie
    Minarik, Marek
    Jancarikova, Dana
    Belsanova, Barbora
    Pesek, Milos
    ANTICANCER RESEARCH, 2010, 30 (05) : 1667 - 1671
12345